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The Wnt signaling pathways play pivotal roles in carcinogenesis.
Modulation of the cell-surface abundance ofWnt receptors is emerging
as an important mechanism for regulating sensitivity to Wnt ligands.
Endocytosis and degradation of the Wnt receptors Frizzled (Fzd) and
lipoprotein-related protein 6 (LRP6) are regulated by the E3 ubiquitin
ligases zinc and ring finger 3 (ZNRF3) and ring finger protein 43 (RNF43),
which are disrupted in cancer. In a genome-wide small interfering RNA
screen, we identified the deubiquitylase ubiquitin-specific protease 6
(USP6) as a potent activator of Wnt signaling. USP6 enhances Wnt
signaling by deubiquitylating Fzds, thereby increasing their cell-sur-
face abundance. Chromosomal translocations in nodular fasciitis re-
sult in USP6 overexpression, leading to transcriptional activation
of the Wnt/β-catenin pathway. Inhibition of Wnt signaling using
Dickkopf-1 (DKK1) or a Porcupine (PORCN) inhibitor significantly de-
creased the growth of USP6-driven xenograft tumors, indicating
that Wnt signaling is a key target of USP6 during tumorigenesis.
Our study defines an additional route to ectopic Wnt pathway ac-
tivation in human disease, and identifies a potential approach to
modulate Wnt signaling for therapeutic benefit.
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Wnts are a family of secreted proteins that regulate keydevelopmental processes during embryogenesis as well as
the homeostasis of adult tissues, including bone, skin, and in-
testine (1). Wnt signaling is a tightly regulated process, and its
deregulation is implicated in various diseases, including cancer
and inflammatory and vascular diseases (2). Wnt ligands interact
with multiple receptors and coreceptors, and the specific com-
bination of ligand and receptor determines which downstream
pathways are regulated. Wnts can signal both through β-catenin–
dependent and β-catenin–independent pathways (3). In the
β-catenin–dependent pathway, Wnt binding to its receptors,
Frizzleds (Fzds) and low-density lipoprotein-related protein 5/6
(LRP5/6), leads to the inhibition of ubiquitylation and proteaso-
mal degradation of cytosolic β-catenin (4). β-catenin is thus sta-
bilized and enters the nucleus, where it binds to the TCF/LEF
family of transcription factors to activate transcription of a mul-
titude of target genes (5).
In addition to controlling β-catenin protein stability, ubiq-
uitylation regulates the subcellular localization and/or stability of
multiple proteins within the Wnt signaling network, most notably
membrane-proximal signaling events. For example, the cytoplasmic
effector protein Dishevelled (DVL) is ubiquitylated by the KLHL12-
CUL3, ITCH, and PDZRN3 ligases, resulting in its degradation or
the endocytosis of Dvl/Fzd complex (6, 7). The turnover of Wnt re-
ceptors Fzd and LRP6 is regulated by the transmembrane E3 ubiq-
uitin ligases ring finger protein 43 (RNF43) and zinc and ring finger 3
(ZNRF3) that promote their ubiquitylation, leading to endocytosis
and lysosomal degradation. RNF43 and ZNRF3 are also Wnt/
β-catenin target genes, and thereby function as negative feedback
regulators of Wnt signaling (8, 9). The activity of RNF43 and
ZNRF3 is regulated, in turn, by the extracellular signaling pro-
teins, R-spondins (RSPO1–4), which form a ternary complex with
RNF43/ZNRF3 and the coreceptors LGR4–6 (8, 10). Either loss-
of-function RNF43 mutations (11, 12) or overexpression of R-
spondin, arising from its translocation, leads to increased surface
levels of Wnt receptors, β-catenin activation, and tumorigenesis
(13, 14). Thus, diverse and tightly regulated ubiquitin ligases play a
pivotal role in controlling Wnt activity.
Like ubiquitylation, regulated deubiquitylation plays a crucial role
in governing information flow within the cell. Ubiquitin-specific
proteases (USPs), one of the most abundant groups of deubiqui-
tylation enzymes (DUBs), have fundamental roles in the ubiquitin
system by specifically deconjugating ubiquitin from targeted pro-
teins. Several DUBs have been shown to regulate components of
the Wnt signaling pathway directly. CYLD functions as a negative
regulator of Wnt signaling by deubiquitylating the cytoplasmic ef-
fector DVL (15), and USP4 modulates Wnt signaling through
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interaction with Nemo-like kinase (NLK) and transcription factor 7
like 2 (TCF7L2) (16). USP34 regulates AXIN1/2 stability and op-
poses its tankyrase (TNKS)-dependent ubiquitylation, hence func-
tioning as a positive regulator of Wnt signaling (17). TRABID also
positively regulates Wnt signaling by deubiquitylating adenomatous
polyposis coli (APC) and regulating the stability of the β-catenin/
TCF transcription complex (18). USP47 and USP4 can directly
regulate β-catenin deubiquitylation (19, 20). USP8 deubiquitylates
endosome-tethered Fzd, resulting in the recycling of Fzd to the
plasma membrane (21). Although genetic alterations in the ubiq-
uitylation machinery have been identified in cancers (i.e., RNF43/
ZNRF3, RSPO3), to date, no mutations in DUBs that activate Wnt
receptors have been documented in human tumors.
Using genome-wide small interfering RNA (siRNA) screens
coupled with focused gain-of-function validation, we identified
USP6 as a potent activator of the Wnt pathway. USP6, which is
overexpressed upon translocation in aneurysmal bone cyst (ABC)
and nodular fasciitis, potentiates Wnt signaling by increasing the
abundance of Fzds and LRP6 at the plasma membrane. We show
that USP6 functions by deubiquitylating Fzds and, as such, an-
tagonizes the activity of the E3 ubiquitin ligases RNF43 and
ZNRF3. Wnt signaling is a functionally important target of USP6,
because pharmacological inactivation of Wnt signaling using a
Porcupine (PORCN) inhibitor significantly attenuates the growth
of xenografts driven by high USP6 expression. Finally, activation
of Wnt signaling is observed in human tumors harboring USP6
translocation, supporting its clinical relevance in regulating Wnt
activity. Our study uncovers a mechanism that controls Wnt receptor
abundance on the cell membrane, and thus provides new targets for
modulating Wnt signaling.
Results
Functional Genomic Screen of β-Catenin–Dependent WNT Signaling.
To identify novel regulators of Wnt signaling, an extensively
validated and near-saturation genome-wide siRNA screen in
HEK293T human embryonic kidney cells and HT1080 human
sarcoma cells was performed. A similar strategy was previously
used in DLD1 cells, a colorectal cancer cell line that expresses a
mutant form of APC that disrupts the β-catenin destruction com-
plex (22). In the current screen, exogenous Wnt ligand was used to
activate receptor-mediated signaling. HEK293T and HT1080 cell
lines with an integrated Wnt/β-catenin–activated firefly luciferase
reporter and cytomegalovirus-driven Renilla luciferase reporter
were screened in the presence of WNT3A-conditioned medium in
1,536-well plates with three nonoverlapping gene-specific siRNAs
in each pool. Of 28,124 siRNA pools targeting 20,042 messenger
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Fig. 1. Genome-wide siRNA screen of WNT/β-catenin signaling. (A and B) Volcano plot of the primary siRNA screen. HEK293T (A) and HT1080 (B) cells are
shown; red dots represent deubiquitylases. Full cross-referenced primary screen data are provided in Dataset S1. The HT1080 screen was published previously
(43). (C) Scatter plot of the secondary siRNA screen. Data points represent genes targeted by a pool and at least two single siRNAs that increased or decreased
the reporter by twofold or greater. Full secondary screen data are provided in Dataset S1. (D) Scatter plot of the secondary siRNA screen. Selected deubi-
quitylases and variance across replicates are illustrated. Normalized luciferase activity (firefly/Renilla) of DUBs whose loss of function regulated the Wnt/
β-catenin reporter activity greater than twofold is depicted. Error bars represent mean ± SD. (E) Focused gain-of-function screen. HEK293T cells were
cotransfected with the Wnt/β-catenin reporter, CMV-Renilla luciferase, and indicated expression constructs. The cells were treated with either control- or
WNT3A-conditioned media overnight. Relative luciferase reporter activity is shown as mean ± SD (n = 3). (F) Loss of function of USP6 negatively regulates
Wnt/β-catenin signaling. HEK293T cells stably expressing the Wnt/β-catenin reporter were transfected with the indicated siRNAs. Sixty hours after trans-
fection, the cells were treated with control- or WNT3A-conditioned medium for 16 h. siRNAs targeting β-catenin (CTNNB1) serve as controls. Data represent
mean ± SD (n = 4).
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RNAs, 1,877 increased or decreased Wnt/β-catenin reporter ex-
pression threefold or greater in both cell lines, with a P value less
than 0.01 (Fig. 1 A and B and Dataset S1). A secondary validation
screen of 1,172 hits from the primary screen was performed by
independently evaluating three to nine nonoverlapping single
siRNAs. Hit-calling criteria for the secondary screen included an
increase or decrease in the Wnt/β-catenin reporter activity of at
least twofold with a Student’s t test P value <0.01. Additionally, at
least two independent siRNAs and the repeat test of the pool
had to meet a statistically significant twofold change. We identified
186 gene products that have an impact on Wnt signaling in both
HEK293T and HT1080 cells (Fig. 1C and Dataset S1). Compiled and
cross-listed genome-wide primary screens fromDLD1, HEK293T, and
HT1080 and secondary screen data from HEK293T and HT1080 are
provided in Dataset S1. The DLD1 primary and secondary screen data
are reprinted with permission from AAAS (from ref. 22).
Of the 86 DUBs in the human genome, the genome-wide pooled
siRNA screens identified 28 DUBs as putative regulators of Wnt
signaling in both HT1080 and HEK293T cells. Secondary screens
revealed seven DUBs that have an impact on the Wnt pathway
activity (Fig. 1D). Silencing USP21 and USP6 significantly down-
regulated Wnt/β-catenin reporter activity in both HEK293T and
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Fig. 2. USP6 activates WNT signaling. (A) Model depicting USP6 alleles. Cysteine (Cys) and histidine (His) subdomains of the USP domain are shown. Ser,
serine; TBC, TBC domain. USP6(CS) harbors a point mutation in the cysteine subdomain. (B) Dose-dependent activation of Wnt signaling by USP6. HEK293T
cells with an integrated Wnt/β-catenin reporter were transfected with increasing amounts of plasmids encoding USP6 or its variants. Cells were incubated
with WNT3A- or control-conditioned media for 16 h before analysis. Data represent mean ± SD (n = 3). (C) USP6 activates Wnt signaling in HeLa cells. HeLa
cells were transfected with plasmids expressing USP6 or its variants and Wnt/β-catenin reporter. The cells were incubated with WNT3A- or control-conditioned
medium for 24 h before analysis. Data represent mean ± SD (n = 7). (D) USP6 activates Wnt signaling in HT1080 cells. HT1080 cells were transfected with Wnt/
β-catenin–firefly luciferase reporter, Renilla luciferase reporter, and the indicated plasmids. Cells were incubated with WNT3A- or control-conditioned media
for 12 h before analysis. Data represent mean ± SD (n = 3). (E and F) USP6 does not activate TGF-β or NRF2 signaling. HEK293T cells expressing SBE (TGF-β)
reporter or antioxidant response element (hQR41) reporter were transfected with USP6 or its mutants. Tert-butylhydroquinone (tBHQ; 50 μM) and
recombinant human TGF-β1 (10 pM) are agonists for the SBE and hQR41 reporters, respectively. Renilla-normalized relative luciferase activity was plotted.
Error bars represent mean ± SD (n = 3). (G) USP6 expression stabilizes cytosolic β-catenin. HeLa cells were transfected with plasmids expressing USP6-HA or its
mutant isoforms and then incubated overnight with WNT3A- or control-conditioned medium. Cell lysates were analyzed for levels of endogenous β-catenin
by immunoblotting. NF-κB p65 subunit was used as a loading control. (H and I) Loss of function of USP6 down-regulates expression of WNT-responsive genes.
HEK293T cells were transfected with three independent siRNAs targeting USP6 transcript. Forty-eight hours after siRNA transfection, the cells were treated
with control- or WNT3A-conditioned medium. Total RNA was isolated, and expression of Wnt target genes AXIN2 (H) and NKD1 (I) was analyzed by
quantitative RT-PCR. Data were normalized to transcript abundance for GAPDH, and represent mean ± SD for biological triplicates.
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HT1080 cell lines, whereas loss of function of USP4 and USP1L
increased pathway activity (Fig. 1D). These findings partially
overlap with previously reported DUBs regulating Wnt signaling,
although several, including CYLD and USP8, were not identified
in our screen.
To confirm and extend these findings further, we performed the
converse experiment, testing whether overexpression of selected
DUBs affects Wnt/β-catenin reporter activity. HEK293T cells were
transfected with the indicated expression constructs, along with the
Wnt/β-catenin firefly luciferase reporter and Renilla luciferase re-
porter. USP6 overexpression strongly potentiated WNT3A-induced
reporter activity, comparable to β-catenin overexpression (Fig. 1E).
In agreement with the siRNA screen data, USP21 and USP26 also
potentiated Wnt signaling, albeit significantly less than USP6. In
addition, because high-throughput siRNA screening is highly
susceptible to artifact and false-positive discovery, HEK293T
cells were transfected with three nonoverlapping USP6-specific
siRNAs that were distinct from the siRNAs used in the primary
and secondary siRNA screens; all siRNAs tested suppressed Wnt
signaling (Fig. 1F).
USP6 Activates Wnt/β-Catenin Signaling in Diverse Cell Types in a USP-
Dependent Manner. The full-length USP6 isoform contains the
USP domain at its C terminus and a TBC (Tre2/Bub2/Cdc16)
domain at its N terminus (Fig. 2A). A naturally occurring
C-terminally truncated splice variant of USP6, USP6(short),
lacks an essential portion of the USP domain and is therefore
catalytically inactive (23). To determine whether USP function is
Fig. 3. USP6 regulates WNT signaling at the level of the Wnt ligand and receptor complex. (A) Inhibition of USP6 induced Wnt signaling by XAV939.
HEK293T cells with integrated Wnt/β-catenin reporter were transfected with USP6 expression plasmid. Following treatment with increasing concentrations of
XAV939 for 16 h, luciferase activity was measured. β-catenin(SA) serves as a control; it is constitutively active and resistant to degradation by the destruction
complex. Data represent mean ± SD. (B) USP6 does not potentiate Wnt/β-catenin signaling induced by GSK3 inhibitor. HEK293T cells stably expressing the
Wnt/β-catenin reporter were transfected with control or USP6 expression plasmids. The cells were treated with 1 μM GSK inhibitor CT99021 for 16 h. Lu-
ciferase reporter activity as measured is expressed as mean ± SD (n = 3). ns, not significant. (C) Inhibition of USP6-induced Wnt signaling by DKK1. HEK293
cells with an integrated Wnt/β-catenin reporter were transfected with USP6 and/or WNT3A and incubated with varying amounts of DKK1. Data represent
mean ± SD (n = 3). (D) LRP6 silencing decreases USP6-inducedWnt signaling. HEK293T cells were transfected with the indicated siRNAs. Forty-eight hours after
siRNA transfection with two independent LRP6 siRNAs (siA and siB) or control siRNA (siCNT), plasmids expressing GFP, USP6, or β-catenin(SA) were transfected
and cells were treated with control- or WNT3A-conditioned medium. Luciferase reporter activity is represented as mean ± SD (n = 4). (E) C59 inhibits USP6-
induced Wnt signaling. HEK293 cells with an integrated Wnt/β-catenin reporter were transfected with USP6 and WNT3A expression plasmids and incubated
with the indicated concentrations of C59. Data represent mean ± SD (n = 3). (F and G) USP6 expression increases LRP6 phosphorylation. HEK293T cells were
transfected with control or plasmids expressing USP6 or its variants before treatment with control- or WNT3A-conditioned media for the indicated duration.
Total cellular LRP6 levels and phosphorylated LRP6 (p-LRP6) levels were determined by Western blot analysis.
E2948 | www.pnas.org/cgi/doi/10.1073/pnas.1605691113 Madan et al.
required for Wnt activation by USP6, we examined Wnt/β-catenin
reporter activation by USP6(short), as well as USP6 with a point
mutation in a key catalytic residue, Cys541→Ser, USP6(CS). As
shown in Fig. 2B, expression of USP6 in HEK293T cells enhanced
Wnt signaling in a dose-dependent manner. In contrast,
USP6(short) and USP6(CS) did not have a strong impact on the
the Wnt/β-catenin reporter activity. Similar results were observed
in HeLa and HT1080 cells (Fig. 2 C and D). Furthermore, using
various dilutions of WNT3A-conditioned medium, USP6 was found
to activate Wnt responsiveness at all doses of treatment (Fig. S1A).
In sum, these results demonstrate that the ubiquitin protease ac-
tivity of USP6 is essential for activation of β-catenin–dependent
Wnt signaling, and that USP6 overexpression activates Wnt sig-
naling in multiple cell types of diverse tissue origin.
To test if USP6 is a general activator of transcription, we ex-
amined whether USP6 overexpression had an impact on the ex-
pression of a TGF-β–responsive reporter [SMAD-binding element
(SBE)] or an antioxidant responsive reporter (hQR41). USP6 over-
expression weakly activated the SBE reporter (threefold), compared
with 90-fold activation by TGF-β1 ligand (Fig. 2E). Moreover, USP6
did not increase transcription from the NFE2L2 transcription factor-
driven hQR41 reporter (Fig. 2F), indicating that USP6 shows spec-
ificity for the Wnt pathway and is not a general transcriptional
activator.
We next evaluated whether USP6 activates endogenous Wnt
signal transduction. Binding of Wnt ligands to Fzd and LRP5/6
receptor complexes transiently inhibits the β-catenin destruction
complex, leading to increased steady-state levels of β-catenin in
the cytoplasm and nucleus. As shown in Fig. 2G, basal as well as
WNT3A-induced total β-catenin protein levels were elevated
following USP6 overexpression. This increase in endogenous
β-catenin by USP6 was dependent on its catalytic activity because
no increase was observed with the catalytically inactive USP6
variants (Fig. 2G). The effect of USP6 is not cell type-specific,
because USP6 increased the expression of the endogenous Wnt-
responsive genes NKD1 and AXIN2 in three cell lines of diverse
origins: HEK293, HeLa, and HT1080 (Fig. S1 B–G). Conversely,
silencing of USP6 using three nonoverlapping siRNAs down-
regulated WNT-induced expression of AXIN2 and NKD1 (Fig. 2
H and I). Although these experiments required ectopic expres-
sion of USP6, taken together with the USP6 siRNA data in
multiple cell lines, they support the identification of USP6 as a
novel potentiator of endogenous Wnt/β-catenin signaling.
USP6 Functions Upstream of the Destruction Complex and Requires
Wnt Ligand–Receptor Interactions. To elucidate the mechanism of
Wnt/β-catenin activation by USP6 further, we conducted a series
of epistasis experiments. We first sought to determine whether
USP6 functions upstream of the β-catenin destruction complex.
The β-catenin destruction complex catalyzes β-catenin phos-
phorylation by AXIN-bound glycogen synthase kinase 3 (GSK3)
and casein kinase 1α (CSNK1A), leading to its ubiquitylation and
degradation. AXIN protein levels are negatively regulated by the
poly(ADP)-ribosylation activity of the TNKS1/2 enzyme. Inhibiting
TNKS1/2 with a small-molecule inhibitor, XAV939, results in
increased AXIN protein levels and, consequently, decreased
β-catenin activity. USP6-induced Wnt signaling was dramatically
inhibited by XAV939 (Fig. 3A) indicating that USP6 activates Wnt
signaling upstream of the β-catenin destruction complex. In con-
trast, XAV939 had no effect on Wnt signaling driven by a stabi-
lized, constitutively active β-catenin mutant (Fig. 3A), confirming
the epistatic specificity of the drug. Inhibition of GSK3 activity
increases β-catenin abundance by preventing β-catenin phosphor-
ylation and its subsequent degradation. With near-complete re-
pression of GSK3 activity by the GSK3 inhibitor CT99021, USP6
failed to enhance Wnt signaling further (Fig. 3B). Together, these
data support a model wherein USP6 potentiates Wnt signaling
upstream of the β-catenin destruction complex.
We next tested whether the interaction of Wnts with their
receptors is required for activation of the pathway by USP6.
Dickkopf-1 (DKK1) is a Wnt antagonist that prevents the inter-
action of Wnts with their coreceptors, LRP5/6. USP6-induced
Wnt signaling was blocked by recombinant DKK1 treatment
(Fig. 3C), suggesting that Wnt-LRP5/6 interaction is required for
USP6 function. Further supporting a requirement for a Wnt
ligand engaged receptor complex, knockdown of LRP6 with two
independent siRNAs inhibited USP6-induced Wnt/β-catenin
reporter activity in HEK293 cells (Fig. 3D). Importantly, sub-
nanomolar amounts of the PORCN inhibitor C59, which effec-
tively blocks Wnt secretion (24), inhibited basal USP6-stimulated
β-catenin signaling, as well as the synergistic activation obtained
upon cotransfection of WNT3A and USP6 expression plasmids
(Fig. 3E).
Binding of Wnts to their cell surface receptors leads to phos-
phorylation of LRP6, which triggers a cascade of events leading to
stabilization of β-catenin. We observed that compared with the
control, LRP6 was more rapidly phosphorylated in USP6-expressing
cells upon treatment with WNT3A CM (Fig. 3F). Consistent with
the observed effect of USP6 in enhancing Wnt signaling, basal as
well as Wnt-induced LRP6 phosphorylation was elevated in USP6-
expressing cells. This activity was dependent on the protease activity
of USP6 because the USP6(short) and USP6(CS) variants were not
active (Fig. 3G). These data suggest that USP6 regulates Wnt
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signaling at the membrane, and that USP6 functions only in the
presence of Wnt ligand secretion and Wnt receptor engagement.
USP6 Regulates Cell Surface Abundance of LRP6 and Fzds. Because
ubiquitylation is a key mechanism regulating Fzds and LRP5/6
membrane abundance, we tested if USP6, as a deubiquitylase,
increased the abundance of the Wnt receptors on the cell sur-
face. A USP6-GFP fusion protein was expressed in HEK293 cells,
and plasma membrane levels of endogenous Fzds were measured
by flow cytometry using the anti-Fzd monoclonal antibody
OMP18R5 (25). Wild-type, but not inactive, USP6 markedly in-
creased the cell surface abundance of Fzds, because 69.5% cells
expressing USP6-GFP had high Fzd levels compared with 4.5% of
GFP control cells (Fig. 4A). Wild-type USP6 similarly increased
the cell surface abundance of endogenous LRP6, with 37.8% of
cells showing high LRP6 levels compared with 3% of the controls
(Fig. 4B). Expression of the catalytically inactive USP6(CS) and
USP6(short) variants had no significant effect on surface LRP6
abundance.
USP6 Does Not Potentiate Wnt Signaling in RNF43 Mutant Cells. E3
ubiquitin ligases RNF43 and ZNRF3 negatively regulate Wnt
signaling by promoting ubiquitylation and degradation of LRP6
and Fzds (8). AsPC-1 cells derived from pancreatic ductal ade-
nocarcinoma (PDAC) have an inactivating mutation in RNF43,
which presumably abrogates Fzd ubiquitylation, leading to Wnt-
driven proliferation in vivo (14). We compared AsPC-1 with Panc
08.13 cells, a PDAC cell line with wild-type RNF43. Consistent
with the loss of the RNF43 ubiquitylation activity, expressing the
ubiquitin protease USP6 in the ubiquitin ligase-deficient AsPC-1
cells caused only a twofold increase inWnt signaling (Fig. 5A); this
residual effect may be due to reversal of some ZNRF3 activity.
Unlike the synergy observed in RNF43 wild-type cells, in AsPC-1
cells, there was no significant enhancement of signaling in the
presence of WNT3A (Fig. 5A). Consistent with the twofold acti-
vation of Wnt signaling, USP6 expression drove only a modest
increase in Fzd membrane abundance (Fig. 5B). In contrast, in
Panc 08.13 cells, both Wnt signaling (Fig. 5C) and Fzd cell surface
abundance (Fig. 5D) were markedly enhanced by USP6 to a degree
comparable to the degree measured in HEK293, HT1080, and
HeLa cells.
These results suggest that USP6 enhances Wnt signaling by
counteracting the effects of the ubiquitin ligases RNF43 and
ZNRF3. We therefore tested if titrated restoration of RNF43
activity in AsPC-1 (RNF43 mutant) cells rescued the synergistic
activation of Wnt signaling by USP6. As indicated by the ratio of
Wnt-stimulated β-catenin reporter activity in the absence or
presence of USP6, restoring the expression of RNF43 modestly
decreased overall signaling but markedly increased the synergistic
activation by USP6 (Fig. 5E). These data are consistent with a
model in which deubiquitylation of Fzds by USP6 increases their
cell surface abundance by reversing their RNF43/ZNRF3-
mediated ubiquitylation.
Because RNF43 increases Fzd endocytosis, we tested if USP6
decreased the clearance of Fzd from the cell surface. HEK293
cells have abundant cell surface Fzd, and when protein synthesis
was blocked with cycloheximide, the Fzd abundance decreased,
presumably due to endocytosis (Fig. 5F, purple lines). However,
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when USP6 was overexpressed, cell surface Fzd markedly in-
creased, and its rate of clearance from the membrane decreased
(Fig. 5F, brown lines). These data are consistent with USP6
working to oppose Fzd endocytosis.
USP6 Regulates Fzd Deubiquitylation. We next tested if USP6 di-
rectly deubiquitylates Fzds. HEK293T cells were cotransfected
with Fzd-V5, FLAG-ubiquitin (Ub), and HA-USP6 expression
plasmids, and treated with control- or WNT3A-conditioned
media. Fzd-V5 was immunoprecipitated using anti-V5 antibody,
and levels of ubiquitylation were monitored by FLAG immuno-
blotting. In immunoprecipitates from control cells, a smear of
high-molecular-weight species corresponding to ubiquitylated Fzd
was detected (Fig. 6A). Overexpression of USP6, but not catalyt-
ically inactive USP6(CS) or USP6(short), strongly reduced Fzd
ubiquitylation.
To determine if USP6 can directly deubiquitylate Fzd, in vitro
deubiquitylation assays were performed. Fzd5-V5 was immuno-
precipitated from HeLa cells cotransfected with Fzd-V5 and
FLAG-Ub expression plasmids. The immunoprecipitated Fzd-V5
was incubated with recombinant GST-tagged USP6 (wild type or a
catalytically inactive point mutant). As shown in Fig. 6B, ubiq-
uitylation of Fzd-V5 was dramatically diminished by USP6, but not
its catalytically inactive variant USP6(CS). USP2, a highly active
nonspecific deubiquitylase, was used as a positive control. The ef-
fect of USP6 on ubiquitylation of endogenous Fzd5 could not be
monitored due to lack of antibodies that efficiently immunopre-
cipitate Fzd5. Nevertheless, these results suggest that Fzd is a direct
substrate of USP6, consistent with the model in which USP6 ac-
tivates Wnt/β-catenin signaling by deubiquitylating Fzd receptors.
Human Tumors Harboring USP6 Translocation Have a Wnt/β-Catenin
Transcriptional Signature. USP6 is implicated in human non-
malignant neoplastic disorders, with chromosomal translocation-
driven overexpression of USP6 occurring in two independent
tumor types, ABC and nodular fasciitis, in ∼70% and 90% of
cases, respectively (26, 27). To determine if a Wnt/β-catenin gene
signature is activated in these tumors, gene expression profiling
by microarray analysis was performed on nodular fasciitis tumors
with confirmed USP6 translocation/overexpression. The cell of or-
igin in nodular fasciitis has yet to be defined, but is of mesenchymal
origin. We compared the nodular fasciitis transcriptome with an
averaged expression profile generated from 27 predominantly
mesenchymal tumors lacking USP6 translocation. This strategy was
used to exclude genes that are general mesenchymal markers or
common indicators of the transformed state, and instead identify
those genes selectively induced by USP6 in nodular fasciitis. Gene
set enrichment analysis demonstrated strong positive correlation
with multiple independent Wnt/β-catenin signatures (28–32), fur-
ther supporting the model that overexpression of USP6 drives Wnt/
β-catenin signaling in human tumors (Fig. 7 and Dataset S2).
Inhibition of Wnt Signaling Prevents Growth of Tumors Overexpressing
USP6. Because USP6 regulates multiple cellular signaling pathways
(23, 33, 34), we assessed the functional importance of Wnt/
β-catenin pathway activation in USP6-driven tumor formation.
Because no immortalized ABC or nodular fasciitis cell lines exist,
it was necessary to express USP6 alleles ectopically in heterolo-
gous cells. Previous studies have shown that mesenchymal NIH
3T3 fibroblasts stably overexpressing USP6 (USP6/NIH 3T3)
serve as a useful cellular model for ABC and nodular fasciitis.
When xenografted into immunodeficient mice, USP6/NIH 3T3
cells, but not control NIH 3T3 cells, formed highly vascularized,
hemorrhagic tumors, recapitulating features of the human neo-
plasms, particularly ABC (34). To test whether USP6-mediated
tumor formation was dependent on Wnt signaling, we introduced
into USP6/NIH 3T3 cells DKK1, a secreted protein that blocks
Fzd receptor activation. As shown in Fig. 8A, USP6 induction of
β-catenin was significantly attenuated by DKK1, compared with
cells expressing USP6 alone. The s.c. xenografting of these cells into
NOG-SCIDmice revealed that USP6-dependent tumor growth was
significantly inhibited by DKK1 expression (Fig. 8B).
The functional role of Wnt activation by USP6 was assessed
further in a second tumorigenesis model. A high percentage of
primary alveolar rhabdomyosarcoma (ARMS) patient samples
express high levels of USP6. Interestingly, however, in all im-
mortalized ARMS cell lines examined, USP6 expression was
down-regulated. Thus, to determine the effects of USP6 in the
context of this cancer, it was expressed under a doxycycline-
inducible promoter in the ARMS cell line, Rh3 (USP6/Rh3) at
levels comparable to the levels in primary ARMS samples. In-
duction of USP6 expression significantly increased the abundance
of endogenous Fzds on the cell surface (Fig. 8C), indicating ac-
tivation of Wnt signaling. The s.c. injection of USP6/Rh3 cells into
NOD-SCID mice led to the rapid growth of tumors. Treatment of
tumor-bearing mice with the PORCN inhibitor C59 inhibited tu-
mor growth by 45% when dosed at 20 mg/kg once daily by oral
gavage (Fig. 8D). Taken together, these data indicate that USP6
overexpression works, in large part, through activation of the Wnt/
β-catenin pathway to drive tumorigenesis. Pharmacological agents
targeting the Wnt/β-catenin pathway may therefore have thera-
peutic efficacy in USP6-overexpressing cancers.
Discussion
Aberrant activation of Wnt signaling promotes the initiation and
progression of diverse tumor types. Accumulating evidence re-
veals that dynamic ubiquitylation/deubiquitylation of Fzd and
LRP6 is a pivotal regulatory mechanism regulating Wnt/β-cate-
nin signaling in a subset of human cancers. Our study further
highlights the importance of maintaining appropriate surface
levels of Wnt receptors for cellular homeostasis. We describe a
major role for the poorly understood human oncogene, USP6, as
a novel potentiator of Wnt signaling in multiple cell types. USP6
functions by deubiquitylating Fzds and perhaps LRP6 receptors,
thereby increasing the abundance of both Fzds and LRP6 at the
cell surface and rendering cells exquisitely sensitive to Wnt
Flag-Ub
Fzd5-V5
USP6-HA short
220
150
105
76
52
_
_
_
_
_
220
150
105
_
_
_
220
150
105
76
_
_
_
_
WCL IP V5 
A B
+ + ++
  (CS)
++ + +
+ + ++ ++ + +
+ +--
Flag-Ub
Fzd5-V5
GST-USP6
+ +
- +
GST
+
  USP6-CS
 USP2
+
+
+
+
+
+
+
+
-
USP6
Fzd-V5
Ub
Wnt3A + + +
-
+
-+ - - --
Ub
Fig. 6. USP6 promotes Fzd deubiquitylation. (A) USP6 promotes Fzd5 deu-
biquitylation in vivo. HEK293T cells were transfected with plasmids encoding
Fzd5-V5, Flag-Ub, and the indicated USP6 constructs, and then treated with
control or WNT3A CM. (Top) Fzd5 was immunoprecipitated using V5, and its
ubiquitylation was detected with anti-Flag antibody. Whole-cell extracts
were blotted with anti-V5 (Middle) or anti-USP6 (Bottom) antibodies. (B) In
vitro deubiquitylation of Fzds by USP6. HeLa cells were transfected with
plasmids encoding Fzd5-V5 and Flag-Ub. Fzd5 was purified using anti-V5 and
then incubated with GST-tagged recombinant USP6 or USP6(CS). Fzd5
ubiquitylation was detected by immunoblotting with anti-FLAG. GST and
USP2 were used as negative and positive controls, respectively. Data are
representative of two independent experiments. IP, immunoprecipitation;
WCL, whole cell lysate.
Madan et al. PNAS | Published online May 9, 2016 | E2951
CE
LL
BI
O
LO
G
Y
PN
A
S
PL
U
S
ligands. USP6 activity appears to reverse the ubiquitylation of
Fzds and LRP6 by RNF43/ZNRF3. Our data show that USP6
stabilizes the membrane pool of Fzd. Ongoing and future ex-
periments will test the hypothesis that increase Fzd at the
membrane occurs through altered ubiquitin-dependent endocy-
tosis of Fzd. In human tumors harboring USP6 translocations,
the consequence is activation of Wnt/β-catenin signaling. Con-
firming the functional importance of USP6-mediated Wnt
pathway activation, inhibition of Wnt signaling either by expres-
sion of DKK1 or treatment with the PORCN inhibitor C59 sup-
presses USP6-mediated tumor formation in murine xenograft
models. Prior studies have shown that loss-of-function mutations
in RNF43/ZNRF3 and translocation-mediated overexpression of
its inhibitor, R-spondin, also drive pathological activation of Wnt
signaling in human tumors. Together, these findings reinforce
the critical role of this regulatory node of the Wnt pathway in
human tumorigenesis.
We have previously reported that USP6 promotes deubiquity-
lation of cargo proteins to prevent their lysosomal targeting and
increase their surface levels through enhanced recycling (35).
USP8/UBPY is also shown to deubiquitylate Fzd, rescuing it from
lysosomal degradation and promoting its recycling to the plasma
membrane (21). USP8 was not identified in our siRNA screen for
Wnt pathway activators, perhaps due to subphenotypic silencing
by the siRNAs. Thus, USP6 and USP8 may possess both re-
dundant and unique functions in regulating trafficking and Wnt
signaling, with cell type and subcellular localization of both the
USPs and cargoes contributing to their specificity. In this context,
it is important to note that the USP6 gene only exists in hominoids,
and thus cannot readily be studied in model organisms (36).
The current analysis demonstrates the importance of USP6’s
deubiquitylating activity in the regulation of Wnt/β-catenin sig-
naling. However, USP6 also contains a TBC domain, which binds
to the ADP ribosylation 6 (ARF6) GTPase and promotes its
activation in vivo independent of its USP domain (37). Recent
studies have shown that ARF6 can activate Wnt signaling by
stimulating MAPK1/ERK activation and phosphatidylinositide
production to promote LRP6 phosphorylation (38, 39). In ad-
dition, ARF6 is reported to regulate endocytosis of Fzd recep-
tors in the context of noncanonical Wnt signaling (40). Hence,
both the deubiquitylase activity and the TBC/ARF6 interaction
may contribute to the USP6-mediated activation of Wnt. This
role of TBC/Arf6 interaction in regulating Frizzled endocytosis
is consistent with our observation that in certain cell types,
USP6(CS), an inactive point mutant of USP6 with an intact TBC
domain, retains residual activity on β-catenin reporters (Fig. 2).
Future studies will examine the role of USP6’s ability to regulate
Arf6 in Wnt receptor trafficking and β-catenin activation.
USP6 translocations are the key etiological agent in two human
tumors, ABC and nodular fasciitis (26, 27). In both, the USP6
rearrangement leads to overexpression of wild-type USP6 protein
in a mesenchymal cell of origin. Although these tumors share
some histological features, they exhibit distinct clinical behaviors
(41): ABC is a locally aggressive tumor that most commonly arises
in bone, whereas nodular fasciitis is a more benign s.c. lesion. Our
recent studies in cellular and mouse models for these tumors
revealed that NF-κB (23, 34) and signal transducer and activator
of transcription 3 (STAT3) are two critical effectors of USP6
during tumorigenesis. Here, we identify Wnt signaling as an ad-
ditional key pathogenic mediator of USP6, supported by the
finding that inhibition of Wnt function markedly slows the growth
of USP6-high tumors. Furthermore, microarray analysis of nodu-
lar fasciitis samples compared with other mesenchymal tumors
supports the model in which USP6 activates a Wnt/β-catenin re-
sponse in vivo. Consistent with the regulation of multiple pathways
by USP6, nodular fasciitis tumors showed activation of gene sig-
natures associated with Wnt/β-catenin and TGF-β signaling (Fig. 7
and Dataset S2), as well as NF-κB and STAT3 activation. The
dysregulated Wnt/β-catenin pathway is also associated with a
subset of cranial fasciitis, further supporting a key role for Wnt
signaling in fibroproliferative lesions (42). Together, these results
implicate the Wnt/β-catenin pathway as a potential therapeutic
target for the treatment of human neoplasms with translocation-
driven overexpression of USP6. Given the role of USP6 in reg-
ulating NF-κB, STAT3, and Wnt signaling pathways, inhibition of
these pathways or inhibition of USP6 by small molecules may
benefit patients with proliferative disorders, such as ABC or
nodular fasciitis, that are driven by overexpression of USP6.
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Materials and Methods
Tissue Culture.HEK293T, HT1080, L-, HeLa, and Panc 08.13 cells were obtained
from the American Type Culture Collection (ATCC) and grown in DMEM
supplemented with 10% (vol/vol) FBS and 2 mM GlutaMAX (Life Technolo-
gies) in a 37 °C humidified incubator with 5% CO2. AsPC-1 cells from the
ATCC were grown in RPMI supplemented with 10% FBS in a 37 °C humidified
incubator with 5% CO2. Selection and passage of HEK293T and HT1080
stable cell lines harboring the Wnt/β-catenin reporter were performed with
1 μg/mL puromycin.
Primary and Secondary siRNA Screens. Near-saturation genome-wide primary
siRNA screens and secondary siRNA validation screens were performed as
previously described (22, 43, 44). For both screens, cells were transfected
with siRNAs for 96 h; 16 h before cell lysis, cells were treated with WNT3A-
conditioned media. The HT1080 primary screen data presented in Fig. 1 have
been previously reported (43).
Luciferase Reporter Assays. For reporter assays in AsPC-1 and Panc 08.13 cells,
cells were plated in 24-well plates and transiently transfected with a β-catenin
reporter plasmid, Super 8xTOPFlash reporter, and 50 ng of control or WNT3A
expression plasmid. Twenty-four hours after transfection, the cells were washed
with PBS and lysed in 0.6% Nonidet P-40 in PBS containing protease inhibitors;
β-catenin reporter activity was measured using firefly luciferase substrate
(Promega). Cell viability was determined using Lactate Dehydrogenase assay
(LDH), which was then used for normalizing the β-catenin reporter activity. For
HEK293T and HT1080 cells, cells were transiently transfected in 48-well plates
with 10 ng ofWnt/β-catenin reporter construct and 5 ng of control plasmid with
Renilla luciferase driven by a constitutive cytomegalovirus promoter, using
Lipofectamine 2000 following the manufacturer’s protocol (Life Technologies).
Twenty-four to 36 h posttransfection, activation of the reporter was measured
as the ratio of firefly to Renilla luciferase activity using the Dual-Luciferase
Reporter Assay System (Promega). The hQR41 reporter was a kind gift from
Jeffery Johnson (University of Wisconsin, Madison, WI). For siRNA experiments,
cells with integrated Wnt/β-catenin firefly luciferase reporter and Renilla
control reporter were transiently transfected with siRNA using RNAiMax
or Dharmafect. Wnt/β-catenin reporter activity was measured 48–60 h
posttransfection. GCmed1 and GCmed2 control stealth siRNAs were obtained
from Life Technologies. siRNA sequences are listed in Table S1.
Immunoblot. For Western blot analysis of LRP6, cells were transfected 48 h
before lysis. Lysis buffer contained 0.1% Nonidet P-40, 0.1% SDS, 10%
glycerol, 25 mM Tris·HCl, 0.25% sodium deoxycholate, 150 mM NaCl, 2 mM
EDTA (pH 8.0), and protease inhibitor mixture (Roche). Equal amounts of
proteins were resolved on a 10% SDS polyacrylamide gel and transferred to
PVDF membranes. Western blots were performed according to standard
methods. The pLRP6 (catalog no. 2568S), LRP6 (catalog no. 3395S), anti-rabbit
IgG-HRP (catalog no. P0448), and anti-mouse IgG-HRP (catalog no. P0447)
antibodies were obtained from Cell Signaling Technology, and the GSK3β and
β-catenin antibodies were obtained from BD Transduction Labs (catalog no.
610201). Anti-p65 was obtained from Santa Cruz Biotechnology (sc-372).
USP6 antibody was previously described (23). The blots were developed
using SuperSignal West Dura substrate (Thermo Scientific) or enhanced
chemiluminescence (Life Sciences). The images were captured digitally using
the LAS-3000 Life Science Imager (Fujifilm).
RNA Isolation and Quantitative RT-PCR. Total RNA was isolated from the cell
lines using an RNeasy kit (Qiagen). RNA was reverse-transcribed with iScript
reverse transcriptase (BioRAD) or RevertAid (Thermo Fisher Scientific). Real-
time quantitative PCR was performed with SsoFast EvaGreen assay Supermix
from BioRad. HPRT and GAPDH were used as housekeeping genes. The
primers used are listed in Table S1.
Flow Cytometry. For flow cytometric analysis of Fzds and LRP6, cells were
seeded in six-well plates and transfected with pEGFP plasmid or plasmids
expressing USP6 or its catalytically inactive variants. Forty-eight hours after
transfection, cells were harvested andwashed with PBS containing 2–5% FBS.
Nonpermeabilized cells were then stained with anti-Fzd antibody (OMP18R5)
(25) or 5 μg/mL LRP6 antibody (MAB1505; R&D Systems) for 45 min. Cells were
washed with PBS, followed by incubation with goat anti-human IgG-APC
(catalog no. 109-135-098; The Jackson Laboratory) or anti-mouse phyco-
erythrin (PE) (catalog no. 115-116-146; The Jackson Laboratory) secondary anti-
bodies for Fzds and LRP6, respectively. The following antibodies were used as
isotype controls: MAB003 (R&D Systems) for LRP6 and human IgG2 (AbD264;
AbD Serotec) for Fzds. Samples were acquired on a BD Fortessa (BD Biosci-
ences), and the data were analyzed using FlowJo software, version 10.0.7.
Ubiquitylation Assays. For in vitro deubiquitylase assays, HeLa cells were
cotransfectedwith Fzd5-V5 and FLAG-Ub. After overnight incubationwith anti-
V5 antibody (catalog no. A7345; Sigma), immunoprecipitates were washed
three times in the lysis buffer [50 mM Tris (pH 7.5), 100 mMNaCl, 2 mMMgCl2,
0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol, 0.7 μg/mL
pepstatin, 1 μg/mL leupeptin, 2 μg/mL aprotinin, 10 mM NEM, and 10 μM
MG132] and with DUB assay buffer [20 mM Tris (pH 7.5), 100 mM NaCl, 0.05%
Tween-20, 0.5 mg/mL BSA, and 5 mM β-mercaptoethanol]. The sample was
divided into equal portions. One aliquot was immediately boiled in sample
buffer, and the other aliquots were incubated with GST or GST-USP6 or its
catalytically inactive mutant (catalog no. 64-0045-050; Ubiquigent) for 1 h at
37 °C. Samples were washed once in lysis buffer, resolved on a polyacrylamide
gel, and blotted with anti-FLAG antibody (catalog no. F1804; Sigma).
To monitor Fzd5 ubiquitylation in vivo, 293T cells were cotransfected with
Fzd5-V5 and FLAG-Ub, with or without USP6-HA plasmids. After lysis, Fzd was
immunoprecipitated with anti-V5 beads overnight at 4 °C. Immunoprecipi-
tated Fzd-V5 was resolved by SDS/PAGE, and the immunoblots were probed
for Ub with anti-Flag antibody.
Animal Care. BALB/c nude mice and NOD-SCID-gamma (NSG) mice were
purchased from InVivos or The Jackson Laboratory. Animals were housed in
standard cages and were allowed access ad libitum to food and water. The
Duke-NUS Institutional Animal Care and Use Committee (IACUC) and
Children’s Hospital of Philadelphia IACUC approved all of the animal studies.
Tumor Implantation and Treatment of Mice. NIH 3T3 (ATCC) and Rh3 (a gift
from Peter Houghton, University of Texas Health Science Center, San Antonio)
cells were stably transfected with doxycycline-inducible USP6 expression plas-
mids as previously described (23). For the NIH 3T3 lines, 2 × 106 cells were s.c.
injected into NOD-SCID mice; for the Rh3, 2 × 106 cells were suspended in 50%
Matrigel and injected s.c. into flanks of NSG mice. Following development of
palpable tumors, mice were treated with Wnt-C59 formulated in 50% PEG400
(vol/vol) in water administered by oral gavage at a dosing volume of 10 μL/g of
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Fig. 8. Inhibition of Wnt signaling prevents growth of tumors with USP6
activation. (A) Coexpression of DKK-1 reduces β-catenin activation in USP6-
expressing NIH 3T3 cells. NIH 3T3 cells transiently expressing USP6 alone or
with DKK-1 were treated with various dilutions of WNT3A CM. Cell lysates
were immunoblotted for endogenous β-catenin and p65 as a control.
(B) Expression of DKK-1 inhibits tumorigenesis of USP6-expressing NIH 3T3
cells. NIH 3T3 cells stably expressing doxycycline-inducible USP6 or USP6 plus
DKK1 were injected s.c. into NOD-SCID mice. Tumors were harvested after
14 d, and tumor weights were recorded. (C) USP6 expression in ARMS cells
increases surface abundance of Fzds. Flow cytometric analysis of cell surface
Fzds in Rh3 cells upon induction of USP6 expression by doxycycline (dox).
(D) PORCN inhibitor prevents growth of ARMS with inducible USP6 expression.
NSG mice were injected s.c. with Rh3 cells expressing doxycycline-inducible
USP6. Following establishment of tumors, the mice were gavaged with vehicle
or 20 mg/kg C59, and tumor weights were recorded on study termination.
Data are represented as mean ± SD (n = 14). P = 0.0003 as determined by
two-way ANOVA.
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body weight as previously described (24). Mice were maintained on 1 mg/mL
doxycycline-containing water during the study duration.
Microarray and Gene Set Enrichment Analysis. Microarray analysis was per-
formed on nine nodular fasciitis tumors with USP6 translocation and 27 addi-
tional tumors, including three each of ARMS, dermatofibroma or benign fibrous
histiocytoma, dermatofibrosarcoma protuberans, synovial sarcoma, embryonal
rhabdomyosarcoma, melanoma, neurofibroma, andmalignant peripheral nerve
sheath tumor; one gastrointestinal stromal tumor; and two schwannomas. Total
RNA was extracted using a miRNeasy FFPE kit (Qiagen), and microarray analysis
was performed using a Human WG-DASL assay with Human HT12 v4.0 Bead-
Chips (Illumina), containing 29,377 probes. Data filtering, normalization, and
analysis were performed using Illumina GenomeStudio and Partek Genomics
Suite software. A total of 20,818 probes remained after filtering. Differentially
expressed genes in nodular fasciitis compared with other tumor types were
analyzed using ANOVA. P values were corrected for multiple comparison.
According to source of variance analyses, the microarray batch (array slide
of 12 samples) was also included as a variable in the ANOVA. Gene set
enrichment analysis was performed using the Hallmark gene set from the
Broad Institute.
Data Analysis. Data were analyzed using Prism, version 5.0 (GraphPad). Sig-
nificance for all tests was set at P ≤ 0.05 unless otherwise stated (*P≤ 0.05, **P ≤
0.01, ***P ≤ 0.001, and ****P ≤ 0.0001 in all instances).
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